SARTORIUS AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 260 USD | +4.00% |
|
+11.11% | -30.29% |
| Jul. 11 | Cooling Inflation in Germany, US Boosts DAX Index | MT |
| Jul. 10 | UBS lowers target for Sartorius to 260 euros - 'Neutral' | DP |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 68.44 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -30.29% | 16.3B | - | ||
| -53.66% | 2.29B | C+ | ||
| +13.44% | 1.79B | - | ||
| -15.91% | 1.4B | - | ||
| +44.35% | 1.38B | B+ | ||
| +5.96% | 833M | - | ||
| -30.52% | 799M | - | ||
| -38.05% | 707M | - | C- | |
| -26.54% | 615M | B+ | ||
| +27.83% | 606M | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SRT3 Stock
- SUVPF Stock
- Ratings Sartorius AG
